April 20, 2024 5:08 am
Gen-2 tACS device shows promising results in clinical study conducted by Nexalin Technology

Mark White, CEO of Nexalin Technology, recently shared the positive outcomes of a clinical trial involving their Gen-2 tACS device for pain reduction in veteran patients with Mild Traumatic Brain Injury (mTBI). The trial was conducted at The University of California, San Diego, in collaboration with the United States Department of Veterans Affairs San Diego Healthcare System, as well as various departments at UC San Diego.

The study involved 24 veteran patients with mTBI who received twelve treatment sessions over four weeks. They were then followed by a four-week observation period to analyze outcomes. Despite being a complex issue for both veterans and the general public, effective treatments for post-concussive symptoms (PCS) are scarce, and there is still much to learn about the underlying causes. Symptoms of PCS often overlap with those of post-traumatic stress disorder (PTSD), making diagnosis and treatment even more challenging.

The results of this study are especially notable given the extensive market potential for therapies addressing traumatic brain injuries. According to Global Market Insights, the Traumatic Brain Injuries Assessment Market is forecasted to exceed $7.2 billion by 2032. Nexalin’s innovative approach shows promise in meeting the needs of individuals coping with mTBI, potentially enhancing their quality of life and offering hope for more effective treatment options in the future.

The use of transcranial alternating current stimulation (tACS) has shown promising results in treating pain and other symptoms associated with mTBI. tACS is a non-invasive procedure that uses electrical impulses to stimulate specific areas of the brain. It has been shown to be safe and effective in previous studies.

Nexalin Technology’s Gen-2 tACS device was used during the clinical trial and was found to be effective in reducing pain levels in veteran patients with mTBI compared to placebo groups.

The encouraging results of this study highlight the need for continued research on therapies addressing traumatic brain injuries such as TBI assessment markets forecasted to grow rapidly by 2032 according Global Market Insights.

In conclusion, Nexalin Technology’s Gen-2 tACS device shows promise in meeting the needs of individuals coping with mTBI and improving their quality of life by providing hope for more effective treatment options in

Leave a Reply